uniQure (NASDAQ:QURE) Now Covered by Analysts at Chardan Capital

Chardan Capital assumed coverage on shares of uniQure (NASDAQ:QURE) in a research report released on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $38.00 price objective on the biotechnology company’s stock. Chardan Capital also issued estimates for uniQure’s FY2025 earnings at ($3.90) EPS and FY2026 earnings at ($3.23) EPS.

A number of other research analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of uniQure in a research note on Tuesday, March 4th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Cantor Fitzgerald increased their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. The Goldman Sachs Group lifted their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. Finally, Stifel Nicolaus increased their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Price Performance

QURE opened at $9.75 on Tuesday. The firm has a 50-day moving average price of $13.38 and a 200-day moving average price of $10.88. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $527.25 million, a price-to-earnings ratio of -1.97 and a beta of 0.37.

Insider Transactions at uniQure

In other uniQure news, CFO Christian Klemt sold 14,341 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the sale, the chief financial officer now owns 152,372 shares in the company, valued at $1,630,380.40. This trade represents a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

A number of large investors have recently modified their holdings of QURE. Point72 Asset Management L.P. grew its position in uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of uniQure in the 3rd quarter valued at $444,000. FMR LLC boosted its stake in shares of uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Sanders Morris Harris LLC grew its holdings in shares of uniQure by 50.0% during the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after purchasing an additional 34,034 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new position in uniQure in the 3rd quarter worth $7,360,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.